SPOTLIGHT -
Irvine, CA-ISTA Pharmaceuticals, Irvine, CA, entered into an agreement with AcSentient Inc. under which ISTA will acquire rights to three late-stage ophthalmology compounds.
Novartis finalizes divestment of ‘front of eye’ ophthalmology assets
EyePod: Week in Review - September 24, 2023
Outlook Therapeutics requests Type A meeting with FDA
EyePod: Transforming the MIGS pipeline into clinical reality
BLOG: MicroPulse TLT for patients who struggle with drops
Digital healthcare startup eyecbetter kicks off Regulation C crowdfunding campaign on StartEngine